Fenil-V

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fenil-V

What is Fenil-V? (Overview)

Property Description
Active Ingredient Diclofenac
Form Available as prolonged-release capsules, tablets, and solution for injection
Pharmacological Class Non-Steroidal Anti-Inflammatory Drug (NSAID)
Common Use Management of pain and inflammation
Origin An international brand name for Diclofenac

Fenil-V is a trade name for the widely known medication diclofenac, which belongs to the class of Non-Steroidal Anti-Inflammatory Drugs, or NSAIDs. This medication is clinically recognized for its properties that help manage symptoms of pain, swelling, and stiffness that arise from various inflammatory conditions.

The medication's core function is to inhibit the body's production of certain chemical messengers, primarily prostaglandins, that are responsible for triggering pain and inflammation signals. Diclofenac’s long history of use and widespread adoption make it a common choice globally for conditions where both pain and swelling are present, such as in the management of arthritis or acute injuries.

While Fenil-V is commonly available in several formulations, including solutions for injection, it is frequently prescribed as a prolonged-release (Retard) capsule in some markets. This specific formulation is designed to release the active ingredient slowly, aiming to sustain its pain-relieving effects over an extended period. The active ingredient itself is a derivative of phenylacetic acid, placing it in a well-studied category of anti-inflammatory agents.

Fenil-V is typically classified as a prescription-only medicine (Rx) in many countries due to its potency, ensuring that its use is overseen by a healthcare professional.

What side effects are possible with Fenil-V?

Possible Side Effects and Safety Information

Fenil-V (diclofenac) is associated with serious, potentially fatal risks, as documented by government regulatory agencies. The most critical safety information relates to the cardiovascular and gastrointestinal systems.


Serious Adverse Reactions

  • Cardiovascular Thrombotic Events: Use of this medicine may increase the risk of serious and potentially fatal cardiovascular events, including heart attack (myocardial infarction) and stroke. This risk may increase with higher doses and longer duration of use. Patients with existing cardiovascular disease or risk factors are at greater absolute risk.
  • Gastrointestinal (GI) Events: Severe and potentially fatal GI adverse events can occur, such as bleeding, ulceration, and perforation of the stomach or intestines. These events can occur without warning symptoms at any time during treatment.
  • Other Serious Reactions: Official documents also cite risks of serious liver toxicity (hepatotoxicity), kidney injury (renal papillary necrosis), new onset or worsening hypertension, fluid retention/edema, severe allergic reactions (anaphylaxis), and serious skin reactions (e.g., Stevens-Johnson Syndrome).

Safety Classifications and Restrictions

  • Dose and Duration: To minimize the potential for cardiovascular and GI risks, regulatory documents recommend using the lowest effective dose for the shortest duration possible.
  • Contraindications: Fenil-V is formally contraindicated (prohibited) for use in the peri-operative setting of coronary artery bypass graft (CABG) surgery. It is also contraindicated in patients with established congestive heart failure (NYHA Class II-IV), ischemic heart disease, peripheral arterial disease, or cerebrovascular disease.
  • Hypersensitivity: The drug is contraindicated in patients with a known history of asthma, hives (urticaria), or other allergic-type reactions after taking aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs).

Adverse Reaction Categorization

Commonly reported adverse reactions, categorized by frequency in clinical trials (e.g., ge 1/100 to < 1/10), include effects in the gastrointestinal, nervous, and skin system-organ classes.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes a Fenil-V (Diclofenac) overdose as potentially serious, with manifestations primarily affecting the gastrointestinal and central nervous systems. Immediate medical attention is required for any suspected overdose.

Documented Manifestations and Severe Outcomes

System Documented Signs/Symptoms
Gastrointestinal (GI) Nausea, vomiting (which may include blood), abdominal pain, diarrhea, and signs of internal bleeding (e.g., black or bloody stools).
Central Nervous System (CNS) Dizziness, drowsiness, confusion, headache, agitation, and, in severe cases, seizures or coma.
Renal/Cardiopulmonary Little or no urine output, high or low blood pressure, and trouble breathing (especially in patients with asthma).

Emergency Actions and Management

Government guidance requires that individuals seek medical help right away and contact their local emergency number or a poison control center immediately. The regulatory profile confirms that no specific antidote is known for Diclofenac overdose. Therefore, management in a clinical setting is symptomatic and supportive, which may involve procedures like activated charcoal administration, gastric lavage, monitoring of vital signs, and diagnostic tests such as an ECG and blood work. Severe outcomes, including acute renal failure and GI perforation, mandate continuous hospital observation.

Therapeutic Uses of Fenil-V

What Fenil-V Treats: Main Uses and Benefits

Fenil-V is commonly used across therapeutic domains where relief from pain and inflammation is the primary goal, and it may help moderate distressing symptoms and support patient comfort. The medication is relevant for easing symptoms related to inflammatory or irritative states.

The medication is frequently used for conditions characterized by periods of heightened symptoms, including chronic inflammatory diseases like rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. It is also relevant in clinical settings that involve acute or unstable symptom patterns, such as managing pain after physical injuries or surgical procedures, or addressing episodic pain like acute migraine attacks or primary dysmenorrhea.

Fenil-V is applied in addressing symptom clusters that may become intense or disruptive, such as chronic pain, tenderness, swelling, and joint stiffness. This supportive relief may help patients cope more steadily with symptom fluctuations.

“It is applied in scenarios where additional management of discomfort is required, helping to ease the overall symptom burden.”

Quick Fact: Used for Managing Inflammatory Pain

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Fenil-V (diclofenac) is a Non-Steroidal Anti-inflammatory Drug (NSAID) whose use is strictly governed by official eligibility criteria from regulatory bodies. Fenil-V is contraindicated and must not be used in the following populations:

  • Individuals with a known history of hypersensitivity or allergic-type reactions (such as asthma, hives, or anaphylaxis) after taking diclofenac, aspirin, or any other NSAID.
  • Patients in the setting of coronary artery bypass graft (CABG) surgery.
  • Patients with established severe cardiovascular disease, including congestive heart failure (NYHA Class II-IV), ischemic heart disease, peripheral arterial disease, and cerebrovascular disease. High-dose, long-term systemic use is specifically prohibited in this group.
  • Individuals with active gastrointestinal bleeding, ulceration, or perforation; hepatic failure; or renal failure.

Restrictions for Use

Use is contraindicated in pregnant women starting at 30 weeks gestation due to the risk of premature closure of the fetal ductus arteriosus. Use is generally not recommended during lactation. The medicine is sometimes authorized for specific uses in pediatric patients (e.g., from 12 months for certain conditions and dose forms), but eligibility is determined by the specific formulation's official labeling.

What should I know about interactions with other medicines?

The official regulatory profile for Fenil-V details specific drug-drug, drug-substance, and administration-timing interactions. Medicinal product categories with documented interactions include other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Anticoagulants, Antihypertensives, Diuretics, Systemic Corticosteroids, and the strong CYP2C9 inhibitor Voriconazole. Specific interacting medicines explicitly listed in regulatory materials include Lithium, Digoxin, and Methotrexate.

The Mechanistic basis of interactions is classified into Pharmacokinetic Modification and Pharmacodynamic Antagonism. For instance, Voriconazole officially increases Fenil-V plasma concentrations due to reduced clearance, while Fenil-V itself can increase the exposure of Lithium and Digoxin, and cause Methotrexate accumulation due to impaired renal excretion. Pharmacodynamic interactions result in an Additive Risk of serious bleeding when combined with anticoagulants or corticosteroids, and a reduced therapeutic effect when co-administered with Diuretics or Antihypertensives.

Interaction-related restrictions formally mandate that use in the perioperative setting of CABG surgery is contraindicated. Timing-based interaction rules stipulate that certain formulations must be taken on an empty stomach to ensure optimal efficacy, and co-administration with alcohol significantly increases the official risk of GI bleeding. Population-specific interaction notes caution that the elderly or renally impaired face a greater risk of renal function deterioration when co-administered with Diuretics or ACE Inhibitors.

Mechanism of Action

Fenil-V (Diclofenac) exerts its biological effect by intervening directly in the chemical pathway responsible for the biosynthesis of pro-inflammatory mediators. Its primary mode of action involves the reversible competitive inhibition of the Cyclooxygenase ( COX) enzyme system, specifically targeting the conversion of arachidonic acid into prostanoids.

Modulation of Nociceptive Signals and Inflammatory Mediators

The mechanism decreases the chemical sensitization of peripheral nociceptors by reducing prostaglandin E2 ( PGE2) synthesis at the site of tissue damage. This reduction also affects local vascular responses, reducing vasodilation and subsequent changes in capillary permeability mediated by pro-inflammatory chemical signals.

Central Pathway Adjustment for Thermoregulation

This mechanism also engages central pathways by reducing PGE2 synthesis within the hypothalamus, the area of the CNS that regulates the body's core temperature set point. This inhibition permits the activation of the body’s natural heat-loss mechanisms, facilitating the return of the body's thermoregulatory set point to baseline, resulting in the physiological adjustment of the elevated thermoregulatory set point.

Dosage and Administration Information

Fenil-V is a prescription antiviral medication, and its effectiveness relies on taking it exactly as directed by your healthcare provider. The dosing frequency and duration are tailored to the specific viral infection being treated and your individual health factors, such as kidney function, which may require a dosage reduction in certain patients.

General Administration Instructions

Action Instruction
Initiation Start taking the medication as soon as possible after symptoms begin. For many viral infections, treatment is most effective when initiated within 24 to 72 hours of the first symptoms.
Swallowing Swallow the tablet or capsule whole with a full glass of water. Do not crush, chew, or break extended-release or delayed-release tablets/capsules.
Food May generally be taken with or without food, but specific formulations may have instructions to take it on an empty stomach to optimize absorption. Follow the instructions on your prescription label precisely.
Duration Complete the full prescribed course of treatment, even if symptoms begin to clear up sooner. Stopping early can allow the virus to multiply and may lead to antiviral resistance.

Managing Doses

  • Missed Dose: If you miss a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular schedule. Do not take a double dose to make up for a missed one.
  • Storage: Store Fenil-V in a closed container at room temperature away from heat, moisture, and direct light, and out of the reach of children.

Always consult your pharmacist or healthcare provider if you have any questions or concerns about your dosing regimen.

Recent Clinical Evidence

Research evidence / Overview of studies for Fenil-V

Evidence for Management of Chronic Inflammatory Joint Conditions

Research into Fenil-V, which contains diclofenac, was studied for use in research settings involving conditions such as osteoarthritis (OA), rheumatoid arthritis (RA), and ankylosing spondylitis. Studies conducted in these areas have largely relied on Randomized Controlled Trials (RCTs) and comprehensive systematic reviews. These investigations were designed to measure changes in outcomes related to physical discomfort and daily functioning.

For conditions like OA, research explored how symptoms evolved in adult populations, with key measurements focusing on standardized scales for pain intensity, changes in joint stiffness, and metrics reflecting daily functioning or activity level. The consistency and high volume of RCT data for these chronic conditions explored symptomatic changes in the immediate to mid-term.

Research Evidence for Acute Pain Relief

Fenil-V was also studied in research contexts involving acute or disruptive episodes. Studies in this domain generally involve short-term, single-episode or single-day trials, focusing on rapid changes in pain intensity. For acute migraine attacks, research primarily utilized placebo-controlled and active-controlled RCTs in adult populations, monitoring the number of participants reporting changes in pain intensity (e.g., pain-free state or headache relief). Similarly, for primary dysmenorrhea and post-injury/surgical pain, research examined acute changes in pain intensity and monitored the measured use of rescue analgesia in the observed populations.

Evidence Gaps and Research Uncertainty

While research describes symptom patterns across multiple indications, several areas remain uncertain. The core clinical evidence focuses on changes measured over weeks or months, and understanding long-term use over several years is primarily informed by large, non-randomized, observational research. Regulatory reviews highlight that long-term outcomes are not well characterized based on trials alone. Additionally, data for certain groups remain insufficient; for instance, comprehensive, dedicated clinical trial data specifically focused on children or pregnant populations often show research limitations.

Key Studies & References

  1. Safety review of diclofenac (Therapeutic Goods Administration - TGA)

Frequently Asked Questions (FAQ)

Common questions about Fenil-V (FAQ)


Q: How quickly should I expect Fenil-V to start working?

Official guidance indicates that the effectiveness of the treatment is associated with administration beginning as soon as possible after symptoms start. This window is often described as being within 24 to 72 hours of the first symptoms. The time until symptomatic relief is felt may vary for each person and condition.


Q: Does Fenil-V treat the cause or just the symptoms?

Fenil-V is a Non-Steroidal Anti-Inflammatory Drug (NSAID) whose primary action is to manage symptoms of pain and inflammation. The mechanism involves intervening in the chemical pathway to inhibit the body's production of pro-inflammatory mediators, such as prostaglandins. This action addresses the signals that contribute to discomfort and swelling.


Q: Is Fenil-V generally considered a long-term or short-term medication?

Official safety information indicates the use of the lowest effective dose for the shortest duration possible to minimize potential risks. This statement describes the intent for short-term use or for limited periods to manage acute symptoms. Studies on use over several years are not well characterized by clinical trials alone.


Q: Why do people sometimes say they feel tired after taking Fenil-V?

Commonly reported adverse reactions from clinical trials include effects in the nervous system. While specific reactions like tiredness are categorized by frequency in official documents, they fall under this nervous system category. If feelings of tiredness are experienced, this is consistent with documented effects within this system category.


Q: Is it normal if I don't feel anything immediately after taking Fenil-V?

The official information indicates that the therapeutic effect is generally optimized when treatment is initiated promptly and continued for the prescribed course. The onset of the full effect may not be immediate upon taking the first dose, and individuals may experience varying timelines for relief.


Q: Can Fenil-V affect my sleep?

Official documents categorize commonly reported adverse reactions by the body system affected, which includes the nervous system. Specific sleep-related reactions or disturbances are included within this category in official documents, though the frequency varies by individual.


Q: What types of over-the-counter (OTC) medicines** interact with Fenil-V?

Documented interaction categories include other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), many of which may be available over the counter. Since Fenil-V is also an NSAID, consideration of other OTC medicines is noted. Always check the ingredients of OTC products for potential overlaps.


Q: Are there any food products I should avoid while using Fenil-V?

The medicine can generally be taken with or without food. However, regulatory rules state that certain specific formulations are designated to be taken on an empty stomach to support optimal efficacy, as directed on the prescription label. No specific food products are commonly restricted in official documents.


Q: Is Fenil-V safe for children?

The medicine is sometimes authorized for specific uses in pediatric patients, such as from the age of 12 months for certain dose forms. Eligibility and appropriate use are determined by the specific formulation's official labeling.


Q: Has Fenil-V been approved in other countries?

Official information notes that the medicine has a long history of use and widespread adoption, making it a common choice globally. This description reflects the medicine’s global availability, which necessitates regulatory authorization in various regions.


Q: What is a contraindication in the context of Fenil-V?

A contraindication is a condition or circumstance, such as active gastrointestinal bleeding or severe cardiovascular disease, where the use of the medicine is not permitted according to regulatory documents due to an unacceptable level of risk.


Q: Is it true that Fenil-V can cause a sensitivity to sunlight?

Commonly reported adverse reactions include effects documented in the skin system-organ class. Specific reactions related to heightened sun sensitivity (photosensitivity) are addressed within this category in regulatory documents.


Q: Can Fenil-V be used at the same time as aspirin?

The medicine is classified as an NSAID, and other NSAIDs are listed as a medicinal product category with documented interaction risks. The factual information is that other NSAIDs, including aspirin, are a category of products with documented interaction risks. Additionally, a known history of an allergic reaction to aspirin is a formal contraindication for Fenil-V.


Q: What is the difference between the tablet and liquid forms of Fenil-V?

Fenil-V is available in multiple forms, including tablets, solutions for injection, and capsules. For example, a prolonged-release capsule is designed to release the active ingredient slowly to sustain its effects over an extended period, which is noted to have a different release profile than an immediate-release tablet.


Q: Are there any known long-term effects of taking Fenil-V?

Regulatory reviews highlight that the long-term outcomes of using the medicine over several years are not well characterized based on clinical trials alone. Most core clinical evidence focuses on changes measured over weeks or months, and official safety guidance indicates the use of the shortest duration possible.


Q: What does the term Black Box Warning mean for Fenil-V?

The term refers to the most critical warnings required by regulatory agencies. For Fenil-V, these warnings detail serious, potentially fatal risks related to the cardiovascular system (e.g., heart attack) and the gastrointestinal system (e.g., bleeding or ulceration).


Q: Does Fenil-V have an effect on mental alertness or driving?

Commonly reported adverse reactions from clinical trials include effects in the nervous system. Specific effects related to mental alertness and the ability to drive or operate machinery are included in this category in the official safety information.


Q: Is Fenil-V often prescribed for conditions not listed in its main uses?

Official research has studied the medicine's use in a variety of conditions, as documented in official studies. These include the management of chronic inflammatory joint conditions like arthritis, as well as the short-term relief of acute pain episodes like migraine attacks.


Q: Can Fenil-V cause dizziness?

Commonly reported adverse reactions are categorized by the body system affected, which includes the nervous system. Specific effects like dizziness are included within this nervous system category in the official documents, though the frequency is variable across individuals.


Q: Is there a particular time of day that is best for taking Fenil-V?

Regulatory rules state that certain formulations are designated to be taken on an empty stomach to support optimal efficacy. However, there is no general regulatory guidance regarding a specific time of day for the medicine.


Q: What does the research show about Fenil-V's use in older adults?

Official documents indicate that the elderly population, especially those with existing renal issues, have a greater documented risk of renal function deterioration when the medicine is co-administered with certain other drugs, such as Diuretics or ACE Inhibitors.


Q: Are there any known genetic factors that affect how Fenil-V works?

The metabolism of the active ingredient is officially linked to the CYP2C9 enzyme system. This link is supported by documented drug interactions with strong CYP2C9 inhibitors, which can affect the medicine's clearance and plasma concentrations.

How should Fenil-V be stored and disposed of?

Fenil-V (diclofenac) requires specific storage and disposal protocols as mandated by regulatory documents to maintain its stability and ensure public safety.


Storage Requirements

Fenil-V must be stored at controlled room temperature, generally between 20 C and 25 C. The product must be kept in its original container, which must be tightly closed to protect the medicine from excessive moisture and humidity. All medication must be stored securely out of the sight and reach of children and pets.


Disposal Instructions

Unused or expired Fenil-V should be disposed of via an authorized drug take-back program. If a take-back option is unavailable, the medicine can be safely discarded in the household trash using the official method of mixing it with an undesirable substance in a sealed bag. Disposal via wastewater is prohibited as per governmental guidance for non-hazardous medicines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fenil-V found in:

A-Z Index: